Cochrane · systematic review · CD011790
Pregabalin for pain in fibromyalgia in adults
Derry, S, Cording, M, Wiffen, PJ, et al. · Cochrane Database of Systematic Reviews · 2016 · Cochrane Library
Pain, Palliative and Supportive CareAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
12
current version
GRADE rated
12
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 4 · 33.3%Low 0 · 0%Moderate 0 · 0%High 8 · 66.7%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Pregabalin compared with placebo for fibromyalgia in studies of classic design
Population: adults with fibromyalgia enrolled in studies of classic design
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
‘Substantial benefit’ (at least 50% reduction in pain) Pregabalin vs placebo | no estimate extracted | 5 studies · 1874 participants | High |
‘Substantial benefit’ (PGIC very much improved) Pregabalin vs placebo | no estimate extracted | 5 studies · 1869 participants | High |
‘Moderate benefit’ (at least 30% reduction in pain) Pregabalin vs placebo | no estimate extracted | 5 studies · 1874 participants | High |
‘Moderate benefit’ (PGIC much or very much improved) Pregabalin vs placebo | no estimate extracted | 5 studies · 1869 participants | High |
Withdrawals due to lack of efficacy Pregabalin vs placebo | no estimate extracted | 5 studies · 1874 participants | High |
Withdrawals due to adverse events Pregabalin vs placebo | no estimate extracted | 5 studies · 1874 participants | High |
Serious adverse events Pregabalin vs placebo | no estimate extracted | 3 studies · 1238 participants | Very low |
Death Pregabalin vs placebo | no estimate extracted | 6 studies · 3460 participants | Very low |
Pregabalin compared with placebo for fibromyalgia in enriched enrolment randomised withdrawal (EERW) studies
Population: adults with fibromyalgia enrolled in EERW studies
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Maintenance of initial therapeutic response of at least 30% pain intensity reduction over baseline and continued treatment at 13 or 26 weeks (equivalent to 'moderate benefit') Pregabalin vs placebo | no estimate extracted | 2 studies · 687 participants | High |
Participants experiencing at least 1 adverse event Pregabalin vs placebo | no estimate extracted | 2 studies · 687 participants | High |
Serious adverse events Pregabalin vs placebo | no estimate extracted | 2 studies · 687 participants | Very low |
Death Pregabalin vs placebo | no estimate extracted | 2 studies · 687 participants | Very low |